Drugs / GLPG0555
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01278095 | Jan → Feb 2011 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01208753 | Sep → Nov 2010 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01023321 | Dec 2009 → Apr 2010 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG0555 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01023321 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL3545249 ↗ |
| Route | Oral | “multiple oral doses of GLPG0555” NCT01023321 ↗ |
| Target | JAK1 | “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL3545249 ↗ |